Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Upworthy

Published

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on design for…

#ultragenyx #additionalphase2 #phase3 #lungdisease #usfda #mereo #orbit #phase3cosmic #denisescotsknight #fda

Full Article